Paclitaxel and epirubicin

Phase 3Small molecule

Paclitaxel and epirubicin is one of 127 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

126

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaActive, not recruiting

Cutaneous MelanomaActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

Pulmonary Large Cell Neuroendocrine CarcinomaActive, not recruiting

Esophageal Squamous Cell CarcinomaPreclinical

Active, not recruiting

Cutaneous MelanomaPhase 3

Active, not recruiting

Triple-Negative Breast CancerPhase 2

Active, not recruiting

Pulmonary Large Cell Neuroendocrine CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

249 competitors in Triple-Negative Breast Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

30 2

Abraxane

Bristol-Myers Squibb

Phase 3

23 3

Keytruda

Merck & Co.

Phase 3

22 4

Halaven

Eisai

Phase 3

12 5

Paraplatin

AAvyxa

Phase 3

28 6

Gemzar

Johnson & Johnson

Phase 3

10 7

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

20 8

Cytoxan

BBaxter Healthcare Corporation

Phase 3

13 9

Xtandi

Astellas

Phase 3

2 10

Tuoyi

SSun Yat-sen University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Esophageal Squamous Cell Carcinoma

NCT04519905

Q4 2031

Phase 3Recruiting

Cutaneous Melanoma

NCT06743126

Clinical

Trials by Indication[1]

Triple-Negative Breast Cancer1 trial

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT01276769·80 enrolled

Selected Advanced Solid Tumors1 trial

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Completed· GSK logo

GSK·Phase 1·NCT02723955·829 enrolled

Pulmonary Large Cell Neuroendocrine Carcinoma1 trial

Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma

Unknown status·SShanghai Chest Hospital·Phase 2·NCT02943798·118 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)

Recruiting·FFudan University·N/A·NCT04519905·320 enrolled

Cutaneous Melanoma1 trial

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Recruiting·IImmatics US, Inc.·Phase 3·NCT06743126·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Paclitaxel and epirubicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paclitaxel and epirubicin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paclitaxel and epirubicin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

Paclitaxel and epirubicin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2031

Trials by Indication[1]

Triple-Negative Breast Cancer1 trial

Selected Advanced Solid Tumors1 trial

Pulmonary Large Cell Neuroendocrine Carcinoma1 trial

Esophageal Squamous Cell Carcinoma1 trial

Cutaneous Melanoma1 trial

References

Drug Info

Quick Facts

Related News